Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8743578 | 0.90 | TSHR (0.54) | ALDH1A1TSHRKDM4EPOLBTACR1 | |
| SCHEMBL5349731 | 0.88 | TSHR (0.52) | ALDH1A1TSHRKDM4EPOLBTACR1 | |
| SCHEMBL4860052 | 0.88 | TSHR (0.52) | ALDH1A1TSHRKDM4EPOLBTACR1 | |
| SCHEMBL23227891 | 0.88 | TSHR (0.52) | ALDH1A1TSHRKDM4EPOLBTACR1 | |
| Propane SCHEMBL8983786 | 0.83 | ALDH1A1 (0.50) | ALDH1A1TSHRKDM4EPOLBTACR1 | |
| SCHEMBL18640775 | 0.83 | TSHR (0.56) | ALDH1A1TSHRKDM4EPOLBTACR1 | |
| SCHEMBL11146323 | 0.81 | TSHR (0.67) | ALDH1A1TSHRKDM4EPOLBTACR1 | |
| SCHEMBL8983816 | 0.80 | ALDH1A1 (0.65) | ALDH1A1IDO1 | |
| SCHEMBL17591252 | 0.80 | ALDH1A1 (0.59) | ALDH1A1IDO1AGXT | |
| SCHEMBL476765 | 0.79 | KDM4E (0.53) | ALDH1A1TSHRKDM4EPOLBTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722721-B2 | SEC-hydroxycyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-05-13 | — | — | US | claimed |
| EP-2686299-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES AS HSL INHIBITORS FOR THE TREATMENT DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-22 | — | — | EP | claimed |
| US-20120238613-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | claimed |
| WO-2012123432-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES AS HSL INHIBITORS FOR THE TREATMENT DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | claimed |
| EP-0587440-A2 | Catalyst component for the polymerisation of olefins and process for preparing olefin polymers using same | NIPPON OIL COMPANY, LIMITED (JP) | 1994-03-16 | — | — | EP | claimed |
| US-20160046620-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | SYNGENTA LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| EP-2978318-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | Syngenta Participations AG (CH) | 2016-02-03 | — | — | EP | disclosed |
| CN-103917535-B | Pyrazole compounds and pharmaceutical use thereof | JAPAN TOBACCO INC | 2015-06-24 | — | — | CN | disclosed |
| WO-2014154487-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-02 | — | — | WO | disclosed |
| CN-103917535-A | Pyrazole compounds and pharmaceutical use thereof | JAPAN TOBACCO INC | 2014-07-09 | — | — | CN | disclosed |
| US-8722721-B2 | SEC-hydroxycyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2686299-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES AS HSL INHIBITORS FOR THE TREATMENT DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| CN-101516817-A | Process for the preparation of trifluoroethoxytoluenes | GRINDEKS JSC (LV) | 2009-08-26 | — | — | CN | disclosed |
| US-6071927-A | Spiro-piperidine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2000-06-06 | — | — | US | disclosed |
| EP-0906315-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1999-04-07 | — | — | EP | disclosed |
| US-5744678-A | NICKEL COMPOUND, ORGANOPHOSPHORUS COMPOUND, ORGANOALUMINUM COMPOUND, CARBON-HALOGEN COMPOUNDS; CATALYST SELECTIVITY | NIPPON OIL CO., LTD. (JP) | 1998-04-28 | — | — | US | disclosed |
| US-5728641-A | Catalyst component for the polymerization of olefins | NIPPON OIL COMPANY, LIMITED (JP) | 1998-03-17 | — | — | US | disclosed |
| WO-1997049710-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-12-31 | — | — | WO | disclosed |
| EP-0758563-A1 | OLEFIN OLIGOMERIZATION CATALYST AND PROCESS FOR THE PREPARATION OF OLEFIN OLIGOMER USING IT | NIPPON OIL COMPANY, LTD. (JP) | 1997-02-19 | — | — | EP | disclosed |
| EP-0587440-A2 | Catalyst component for the polymerisation of olefins and process for preparing olefin polymers using same | NIPPON OIL COMPANY, LIMITED (JP) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238613-A1 | SEC-HYDROXYCYCLOHEXYL DERIVATIVES | SEC61B, SEC61A1, SEC22B | ALDH1A1 3041/4885TSHR 1396/4885KDM4E 3279/4885 |
| US-20160046620-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | CRY1, DDT, CYC1 | ALDH1A1 2272/4885TSHR 1000/4885KDM4E 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.